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Abstract
Staphylococcus aureus phage ISP was lyophilized, using an Amsco-Finn Aqua GT4 freeze dryer, in the presence of six
different stabilizers at different concentrations. Stability of the lyophilized phage at 4uC was monitored up to 37 months and
compared to stability in Luria Bertani broth and physiological saline at 4uC. Sucrose and trehalose were shown to be the
best stabilizing additives, causing a decrease of only 1 log immediately after the lyophilization procedure and showing high
stability during a 27 month storage period.
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Introduction
Phage therapy has attracted intense renewed scientific and
public interest, mostly as a consequence of the increasing problem
of antibiotic-resistant strains emerging worldwide. While the
number of phage research articles and well-defined trials is
increasing [1,2,3,4] there is still a lack of information about proper
pharmaceutical formulations and preservation conditions guaran-
teeing effective outcome of phage therapy.
In general, phage preparations applied with therapeutic aims
are produced in liquid formulation, and the storage period of such
preparations, at 4uC, is considered as limited to one year.
Recently, different novel approaches have been described, such
as encapsulating phages into different biodegradable materials
[5,6,7] and aerosols [8,9]. These approaches mostly involve the
use of lyophilized bacteriophages. The methods of lyophilization
described in these studies vary significantly with regard to both
stabilizers and freeze-drying regimes. The most detailed studies on
lyophilization of bacteriophages date back to the 709s of the last
century [10,11,12,13,14] (Table 1). In this study, we optimized the
lyophilization process of the therapeutically important bacterio-
phage ISP, active against strains of Staphylococcus aureus including
MRSA, and explored in more detail the properties of different
modern pharmaceutically acceptable stabilizers.
Materials and Methods
Bacteria and Bacteriophages
Phage ISP is maintained in the phage collection of the LBR
(University of Ghent, Belgium) since 2002 and was received from
the Eliava IBMV (Tbilisi, Georgia). For the propagation of the ISP
phage, we used Staphylococcus aureus strain ‘13 S44 S9’, isolated from
a burn wound at the Brussels Burn Wound Centre (Queen Astrid
Military Hospital, Brussels, Belgium) in 2006.
Phage Propagation and Enumeration
The bacterial strain and the phage were cultured in Select
Alternative Protein Source Luria Bertani (APS LB) (Becton
Dickinson, Erembodegem, Belgium) media. The agar overlay
method with modifications as described earlier [15] was used to
obtain high titer (11 log pfu/ml) phage lysates. Briefly, 1 ml of
phage suspension containing 4 log pfu of ISP was mixed with
3.0 ml of molten (45uC) APS LB top agar (0.7%) and 0.1 ml of a
host bacterial suspension (end concentration of 8 log cfu/ml). This
mixture was plated onto Petri dishes, filled with a bottom layer of
1.5% APS LB agar and incubated at 37uC for 16–18 h. The top
agar layer was scraped off and centrifuged for 20 min at 6 000 g.
The supernatant was filtered through a 0.45 mm membrane filter
(Sartorius Stedim Biotech, Go¨ttingen, Germany).
The obtained phage lysate was ultracentrifuged at 25000 g for
1 h at 4uC and the pellet was resuspended in the same volume of a
0.9% NaCl solution. Phage particles were enumerated by the agar
overlay method [15]. Briefly, decinormal serial dilutions (from
log(0) to log(210)) of the bacteriophage suspension were prepared.
One ml of each dilution was mixed with 3.0 ml of molten (45uC)
0.7% LB top agar and 0.1 ml of a host bacterial suspension (end
concentration of 8 log cfu/ml) and plated in triplicate onto 90 mm
diameter Petri dishes (Plastiques Gosselin, Menen, Belgium), filled
with a bottom layer of 1.5% LB agar and incubated for 18–24 h at
37uC. To estimate the original bacteriophage concentration, plates
with 100–1000 plaques were counted. Each titration was
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performed three times. The mean was then calculated for the
triplicate plates and for each titration.
Lyophilization
Bacteriophage solutions were prepared using the following six
stabilizers with two different concentrations: 0.1 M and 0.5 M for
sucrose, trehalose, mannitol and glycine (BASF, Ludwigshafen,
Germany) and 1% and 5% for PVP (polyvinylpyrrolidone) (BASF,
Ludwigshafen, Germany) and PEG 6000 (polyethylene glycol)
(Fagron, Waregem, Belgium).
Phage stock solution (11 log pfu/ml) was diluted in stabilizers to
a final titer of 8 log pfu/ml for the first series of tests and 9 log
pfu/ml for the second series. Ten-ml freeze-drying vials, contain-
ing one ml of phage solutions, were lyophilized in an Amsco-Finn
Aqua GT4 freeze dryer (Amsco, Hu¨rth, Germany), using the
following lyophilization cycle: prior to loading the vials into the
freeze dryer the shelves were pre-cooled to 25uC. After loading,
the vials were cooled to 230uC at a cooling rate of 1uC/min. A
temperature of 230uC was maintained during 80 min to ensure
complete solidification of the material. Primary drying was
performed at 230uC and 300 mbar during 1000 min. For
secondary drying the temperature was gradually increased from
230 to 25uC over a period of 550 min, followed by an isothermal
period at 25uC during 360 min. The pressure during secondary
drying was maintained at 300 mbar. After freeze-drying, the vials
were sealed at atmospheric pressure using Omniflex stoppers
(Helvoet Pharma, Alken, Belgium). Twenty replicates were made
for each concentration of each stabilizer.
Lyophilized phages were stored at 4uC and checked for stability
after different periods.
Phage Stability Tests
Lyophilized phages, phage particles suspended in LB broth
(10 log pfu/ml) and in non-buffered 0.9% NaCl solution (9 log
pfu/ml), stored at 4uC were monitored for the maintenance of
stability during a maximum of a 37 month period. In case of
lyophilized phages, the freeze-dried cakes were reconstituted by
adding 1 ml of sterile 0.9% NaCl solution and serial dilutions were
performed. Phage enumeration tests were performed in triplicate
by agar overlay method [15], as described above.
Comparison of Phage Genomes
DNA homology of bacteriophages ISP (GenBank: FR852584.1)
and Sb-1 (GenBank: HQ163896.1) was compared by EMBOSS
stretcher [16].
Transmission Electron Microscopy
Resuspended lyophilized samples of ISP were analyzed by
transmission electron microscopy as described in Merabishvili et al.
[15]. The samples were analyzed using a Technai Spirit
transmission electron microscope (FEI, Eindhoven, The Nether-
lands) operating at 120 kV. Micrographs were recorded using a
bottom-mounted digital camera (Eagle, 464K, FEI).
Results and Discussion
ISP is a virulent myovirus, representative of morphotype A1
[15] widely used since decades for therapeutic purposes in
Georgia. ISP represents the main component of the Intravenous
Staphylococcal Phage preparation produced in the 70–80’s by the
Eliava IMBV. Lately, ISP was included in a quality-controlled
prepared phage cocktail BFC-1, used for a pilot safety study in
Belgium [15], and its genome sequence has been determined [17].
According to different studies, ISP is active against 86% [17] –
91% [15] of the clinical isolates of S. aureus, including MRSA. ISP
as a broad-host-range phage is considered as an appropriate
candidate for production of monoclonal phage preparations.
Genome sequence analysis revealed that Myovirus ISP is closely
related to the ‘Twort-like viruses’ [17]. The genome of ISP is
99.5% and 90.6% identical to the genome of phages G1 [18] and
Sb-1 [19], respectively, as determined by EMBOSS stretcher
[16,17]. The genome sequence analysis of ISP confirmed the lytic
character of ISP and the absence of toxin genes [17].
Because, based on these different characteristics, ISP is a phage
with high therapeutic potential, it seemed to be an appropriate
candidate to study the lyophilization optimization process,
applicable for long storage of bacteriophages and for their further
incorporation in different pharmaceutical formulations.
In general lyophilization process generates a variety of freezing
and drying stresses, such as solute concentration, formation of ice
crystals, pH changes, etc. All of these stresses can cause
destabilization of the processed biological material or biomolecules
to various degrees [20].
Therefore special stabilizers must be added to protect these
fragile systems from freezing stress (cryoprotectant) or drying stress
(lyoprotectant) and also to increase its stability upon storage [21].
Six stabilizers representing various groups of common stabilizers
were chosen for the first set of tests performed on ISP phage. Each
stabilizer was applied in two different concentrations. Figure 1
presents the stability of the ISP lyophilisates, for each stabilizer.
PVP, representative of polymer excipients, inactivated the phage
completely at both concentrations (1 and 5%), even prior to
lyophilization. Stabilization of proteins by polymers is generally
attributed to preferential exclusion, surface activity, steric
hindrance of protein – protein interactions, and/or increased
solution viscosity limiting protein structural movement [20].
However in our study PVP proved to be absolutely unacceptable
for lyophilization of ISP phage.
Another stabilizer without any effect appeared to be glycine.
Complete phage inactivation immediately after lyophilization was
observed with both concentrations of 0.1 and 0.5 M Glycine is
important in the lyophilization process mostly as a bulking agent
and tonicity adjuster, but at the same time glycine alone has a
minimal protective effect because it tends to crystallize during
freezing. Glycine as a crystalline bulking agent is more suitable for
lyophilization of small-chemical drugs and some peptides [20].
The sugar alcohol mannitol presents also one of the common
excipients but mannitol in comparison with other sugars can be
easily crystallized and its crystallization is responsible for the
destabilization of some proteins during lyophilization. In general
mannitol appears most effective in combination with other
stabilizers [20]. Freezing rate also influences the extent of
crystallization of mannitol which may potentially affect protein
stability and reconstitution.
Also in our case, no phage activity was detected after
lyophilization in mannitol at a concentration of 0.1 M and a
4 log decrease in phage titer was observed at 0.5 M, caused by the
lyophilization procedure itself. This was followed by stable
maintenance of the same titer throughout 27 months and a
2 log decrease after a 37 month storage period.
A polyhydric alcohol such as PEG is among the most commonly
used and effective cryoprotectants. PEG can be affiliated to two
different groups of excipients, i.e., polymers and non-aqueous
solvents [21]. Immediately after lyophilisation, a 1.8 and 5.0 log
decrease of the ISP titer was detected for 1 and 5% PEG 6000
preparations, respectively. Activity of ISP during storage dimin-
ished gradually, resulting in a final 3 log (for 1% PEG 6000) and a
ISP Phage Lyophilization
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1.7 log pfu/ml (for 5% PEG 6000), after the 37 month storage
period.
Nowadays the most popular cryoprotectants are sugars. The
mechanism of their cryoprotection implies vitrification during
freezing and formation of glass matrix within which phages (in our
case) are prevented from aggregation which protects them against
mechanical stress of ice crystals [21]. It is generally accepted that
among all sugars trehalose is the most preferable cryoprotectant
for biomolecules due to its minimal hygroscopicity, the absence of
internal hydrogen bounds which allows more flexible formation of
hydrogen bonds with proteins during freeze-drying, a very low
chemical reactivity and finally, a higher glass transition temper-
ature [21]. In our study, trehalose, along with sucrose, also proved
to be the the most effective stabilizer, in particular at a
concentration of 0.5 M: approximately only one log decrease
was observed as an immediate loss and further on one log decrease
was observed at this concentration for both stabilizers after a 37
month storage period.
Transmission electron microscopy of the lyophilized samples
showed that in the samples with decreased phage activity number
of intact phage particles was drastically reduced due to their
complete lysis or the destruction, as depicted by loss of tails and by
uranyl-acetate-penetrated heads. The phage particles were asso-
ciated mostly with bacteriophage debris, forming agglomerates,
often by tail-tail interactions. The samples differed from each other
mostly by the number of intact phage particles, without other
significant specific changes. Therefore Figure 2 presenting ISP
lyophilized in mannitol 0.5 M can be considered as an example of
the common picture seen in all lyophilized samples.
Based on the results of the first set of experiments, as determined
after a 10 month period, the best two out of the six tested
stabilizers, i.e. sucrose and trehalose, were chosen for further
detailed study. The level of stabilization afforded by sugars
generally depends on their concentration [21]. The results of a
number of studies [7,10,11,12] show that various concentrations
are optimal for different phages. Therefore, four different
concentrations of each of these stabilizers, i.e. 0.3, 0.5, 0.8 and
1.0 M were applied (Figure 3). The starting titer of ISP in the
second set of experiments was 9 log pfu/ml, instead of 8log pfu/ml
as in the first set of experiments. The immediate decrease in titer
after lyophilization varied between 0.6 and 1.4 logs and the best
results were obtained in case of 0.8 and 1.0 M sucrose with loss of
only 0.4–0.5 logs (Figure 3). During the 27 month storage period,
the activity of ISP stayed stable with variations within one log in all
preparations of sucrose and trehalose, except for 0.3 M of
trehalose.
As a control, phage stability was also monitored in LB broth and
in physiological saline (0.9% NaCl) for the same period at 4uC
(Figure 4). Phages stayed stable in LB broth for one year and a one
log decrease was observed only after the 21 month period, while in
physiological saline phage activity decreased gradually by each log
after 12, 21 and 37 months resulting in a final 6.7 log pfu/ml.
Table 1 summarizes phage lyophilization studies, dating back to
at least 1962, and carried out mostly for well-known E. coli phages.
Duration of storage periods that have been checked ranges from 7
days to 20 years. Comparison of the data is difficult, because very
different stabilizers at different concentrations, different initial
phage titers and different storage temperatures have been used,
and/or because parameters, such as storage temperature, have not
been documented and/or titer changes have been expressed in
different manners.
Thus far, phages have been lyophilized most frequently in
normal culture media with addition of gelatin, peptone and some
sugars at different concentrations [10,11,12,13]. It is also
important to notice that most of the stabilizers used in the studies
at the end of the last century with the aim to optimize phage
storage conditions, nowadays are not pharmaceutically acceptable
any more. In our study, all stabilizers were chosen taking into
Figure 1. Stability of ISP (8 log pfu/ml) in six different stabilizers after freeze-drying procedure and storage at 46C. The results are the
mean values of three titrations. Standard deviations are indicated.
doi:10.1371/journal.pone.0068797.g001
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account this particular criterion. In a number of studies
[10,11,12], sugars, in particular sucrose, proved to be effective
cryoprotectants for phage lyophilization and one of the best results
were obtained in case of 14 phages active against Corynebacterium
spp., lyophilized in the presence of 10% sucrose [10].
In most of the studies (Table 1), the storage period after
lyophilization either is not implied or is limited to several months.
However the longest post-lyophilization storage period thus far
studied lasted 20 years [22], indicating that the phage particles
remained viable, but without specifying the exact titers before and
after lyophilization/storage. In three other studies [10,23,24] the
storage period also comprises several years (from 2 to 18) during
which lyophilized phages showed high stability with a maximum
2 log decrease. In two of these studies [23,24], skim milk was used
as a stabilizer and the third study [10] used more complex media,
consisting of 20% peptone +10% sucrose +2% sodium glutamate.
Four studies on lyophilization and storage stability involving a
relatively large number of phages (from 14 to 25), clearly indicate
that phage survival rate also strongly varies from phage to phage
and does not necessarily depend on only processing conditions
[10,22,23,24]. The phages used in these studies belong to different
morphological families and are active against different species of
bacteria. Based on all the studies presented in Table 1, it can be
assumed that there is no similarity of survival rate even between
very closely related phages lyophilized in the same conditions, for
e.g. such as T3 and T7 [11]. Therefore, lyophilization conditions
must be defined and adjusted for each phage individually which
makes pharmaceutical formulations of therapeutically important
phages more elaborative especially regarding phage cocktails.
Interesting novel approaches have been presented in several
recent studies (Table 1). Anany et al. [25] investigated the
effectiveness of phages immobilized on cellulose membranes with
Figure 2. Transmission electron micrograph of lyophilized ISP sample in 0.5 M mannitol.
doi:10.1371/journal.pone.0068797.g002
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Figure 3. Stability of ISP (9 log pfu/ml) in two different stabilizers after freeze-drying procedure and storage at 46C. The results are
the mean values of three titrations. Standard deviations are indicated.
doi:10.1371/journal.pone.0068797.g003
Figure 4. Stability of ISP (10 log pfu/ml) in LB broth and 0.9% NaCl (9 log pfu/ml) at 46C. The results are the mean values of three
titrations. Standard deviations are indicated.
doi:10.1371/journal.pone.0068797.g004
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further application in meat preservation and Alfadhel et al. [26]
and Puapermpoonsiri et al. [6,7] evaluated the potency of
therapeutic phages, encapsulated in biodegradable microspheres,
for in vitro application of nasal inserts harboring certain doses of
the same phages. All authors implied application of lyophilized
phages in their novel formulations and therefore different
stabilizers/conditions were tested to define most favorable
conditions for maximal phage activity. However, in most of the
experiments shelf-life preservation either was not considered at all
or was limited to maximum several month period.
Conclusion
In conclusion, we found that sucrose and trehalose proved to be
quite effective stabilizers for lyophilization and long term
preservation of bacteriophage ISP. The most efficient concentra-
tions for these stabilizers in this study were 0.8 and 1.0 M with
maximal loss of 0.6 log10s after lyophilization procedure and
steady stability during a storage period of 27 months. Our findings
are also comparable with the results of most studies reviewed here
and presented in Table 1 according to which overall titer losses
usually range between 1 and 3 logs, i.e., between 90 and 99.9% of
the initial titer.
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